SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

07 Apr 2025 Evaluate
Sun Pharmaceutical Industries has informed that it enclosed a copy of the Press Release about Sun Pharma introducing a novel class of drug, Fexuclue®(Fexuprazan) in India for the treatment of Erosive Esophagitis, which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma. Inds. Share Price

1939.60 -20.40 (-1.04%)
05-Aug-2026 09:55 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1939.60
Dr. Reddys Labs. 1163.60
Cipla 1450.30
Lupin 2371.70
Zydus Lifesciences 1113.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: